Lv2
170 积分 2023-04-11 加入
Fibroblast growth factor receptor 1/Klothoβ agonist BFKB8488A improves lipids and liver health markers in patients with diabetes or NAFLD: A phase 1b randomized trial
24天前
已完结
Efimosfermin alfa (BOS-580) once per month in people with metabolic dysfunction-associated steatohepatitis with F2 or F3 fibrosis: results from a 24-week, randomised, double-blind, placebo-controlled, phase 2 trial
3个月前
已完结
[Guidelines for the prevention and treatment of metabolic dysfunction-associated (non-alcoholic) fatty liver disease (Version 2024)]
5个月前
已完结
Updating the recommendations for treatment of tardive syndromes: A systematic review of new evidence and practical treatment algorithm
8个月前
已完结
Tardive Dyskinesia with Antipsychotic Medication in Children and Adolescents: A Systematic Literature Review
8个月前
已完结
Shedding light on FGF21: A potential negative regulator of PCSK9
8个月前
已完结
Severe hypertriglyceridemia: Existing and emerging therapies
9个月前
已完结
Efimosfermin alfa (BOS-580), a long-acting FGF21 analogue, in participants with phenotypic metabolic dysfunction-associated steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2a trial
9个月前
已完结
Pegozafermin led to significant metabolic benefits, in addition to robust beneficial effects on the liver, in an open-label cohort of a Phase 1b/2a study in subjects with non-alcoholic steatohepatitis (NASH)
9个月前
已完结
Safety and efficacy of GLP-1/FGF21 dual agonist HEC88473 in MASLD and T2DM: a randomized, double-blind, placebo-controlled study
9个月前
已完结
皖公网安备34019202002308
